Precision BioSciences Inc 뉴스 - DTIL | 주식 나스닥

개인 투자자를 위한 전문가급 도구.

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure...

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

tw0122 2 주 전

Gene editing news $5 to $7s next

I think they did, but there are still a lot of vampires sucking away at the (limited) revenue.

Why they hired a Chief People Officer instead of of trimming head count? another GNCA IMO

👍️0

jondoeuk 9 월 전

Management can try and spin this as much as they want, but this is a failure https://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics

👍️0

jondoeuk 10 월 전

If one of the companies that are developing off-the-shelf succeed, I don't see why any insurer will pay the price tag of an autologous therapy (assuming similar data/success). On paper, it should be easier than oncology.

👍️0

Monksdream 11 월 전

DTIL 10Q due March 13

👍️0

jondoeuk 11 월 전

That didn't take long! https://www.businesswire.com/news/home/20240301968620/en/Precision-BioSciences-Announces-40.0-Million-Offering-of-Common-Stock-and-Warrants

Maybe things are going slower on the clinical front or no milestone payments are expected.

👍️0

rtrstock 11 월 전

What do you mean an offering?

👍️0

surf1944 11 월 전

Precision BioSciences, Inc. (DTIL) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, February 14, 2024. In conjunction with the reverse split, the CUSIP number will change to 74019P207

The 1 for 30 R/S will make it easy is come out with an offering in the next week or so.

👍️0

rtrstock 11 월 전

1 for 30 not bad, but still will have to hold a long time to get my money back, if I ever do, averaged in at maybe 1.30, so uncertain what price will need to be after reverse split eventually to even break even. Wanting to hold long and make money eventually, but unsure if that's still possible.

I have 5100 shares, so that will be cut to practically nothing, it'd have to go to nearly 50.00 a share for me to make my money back?

Is this correct? Is basically everyone even the big investors like Lilly and Cargill losing big on this one?

👍️0

jondoeuk 12 월 전

Now there will be one. The BOD approved a 1-for-30 R/S. It will become effective at 5:00 p.m. ET on Feb 13. The uncertainty has been eliminated.

👍️0

rtrstock 12 월 전

Guess I'll hold even if there is a R/S

👍️0

jondoeuk 1 년 전

I thought they would, but it seems to me that they want to allow the clock to run before they set a R/S. Looking at the filing, it leaves the effective date to the BOD's discretion. It also gives the them the discretion to abandon it. The company has until the 22nd of April for the stock price to attain what is needed, thereby keeping its listing.

👍️0

NY1972 1 년 전

Side dish becomes the main course. High paid bio CEOs need another bait and switch.

👍️0

jondoeuk 1 년 전

Autoimmune diseases are clearly the next frontier for CAR-T/NK cell therapies, with numerous biotech and (big) pharma companies in the space https://finance.yahoo.com/news/precision-biosciences-completes-license-deal-120000510.html

👍️ 1

81vette 1 년 전

Res. Breakout,after hours could get fun

11th most newly watched ticker,do dd,others are

👍️0

81vette 1 년 전

The 2.5m buy, should open some eyes

👍️0

81vette 1 년 전

Death hour is over,mid day vol surge coming,this pennant has gotten pointy/pokey/stabby(technical terms lol)held strong with .4333 last low bounce,demand growing now,waiting for thru .44 to send it higher

👍️0

81vette 1 년 전

DTIL astronomical potential=greed/hold,tutes own 27%,insiders 21%,100M cash(no offerings),eps this year up 60%/sales past 5years up 102%(tells me sales have started and that explains tutes,I expect they buy more now) 27%below the sma200(so it’s got at least that much run room) target price 2.62, 198 employees,bullish chart since Oct 30th,could be some bashers because it is optionable/shortable,institutional could send this flying up,relative buying vol up 148Xs today ,shares available to short is dropping but still 3.5M(was 4.3m) overall I like that I can put this in my portfolio for long(or until chart breaks) and not have to watch it like a nail biting pump and dump,I have too many of those already lol

👍️0

rtrstock 1 년 전

What indication of a RS is there? Or is it assumed?

This looks like a good buy to me, am I wrong?

👍️0

NY1972 1 년 전

Plenty dead bios walking in this mkt. still handing out options like clock work.

👍️0

NY1972 1 년 전

This bio is walking dead. Failure to let go the PhDs and CARTs a few years ago costed hundreds millions. ARCUS will be bought by IECure after the cash dries up.

👍️0

jondoeuk 1 년 전

Yes, but I think the R/S will happen.

So, at 4:30pm the day before Thanksgiving, they announce a special meeting to vote on a R/S. It will take place on Thurs, Jan 18, '24, at 11:00 am, Eastern Time, at a ratio ranging from 1-for-10 and 1-for-30.

👍️0

Sirpeter 1 년 전

Moving up nicely...looks good

👍️0

knrorrel 1 년 전

nice chart, bottom now and here, Now get the news out and let's see what happens, maybe we'll almost never see these low prices down here on the ground again.
imho

👍️0

knrorrel 1 년 전

News Out, should running hard in good News
imho

👍️0

knrorrel 1 년 전

a really nice $DTIL News https://ih.advfn.com/stock-market/NASDAQ/precision-biosciences-DTIL/stock-news/92484281/precision-biosciences-reports-third-quarter-2023-f

👍️0

rtrstock 1 년 전

Well on stock twits they are saying there is no filed reverse split and that they are expecting an extension to be filed, so I hope you are right. I'm uncertain what all is going on, but I like what this company is doing with it's aspirations in medicine, so staying with it. Just accumulated more, lowered my average cost.

👍️0

konshe 1 년 전

bottom rebound coming, time to buy.

DTIL new 52 wewek low

👍️0

NY1972 1 년 전

DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim the expenses to make sure there will be cash left for clinical trials. High burn and lots of GT bios spell doom for this bio.

👍️0

jondoeuk 1 년 전

I should have pointed out that companies are happening to develop small[er] nucleases. Here is one paper from Casebia Therapeutics, which is a joint venture between CRSP and BAYN https://www.nature.com/articles/s41467-021-24454-5

Also, in 2020, researchers led by Dr. Liu created a new base editor that could perform C-to-T conversion of DNA in mitochondria. However, it had limitations, not only being restricted to that conversion, but mostly limited a certain motif. This means that it could correct only 10% of confirmed pathogenic mitochondrial point mutations https://www.nature.com/articles/s41587-022-01256-8

Last year another novel base editor was created that could achieve A-to-G conversion. Being able to perform that could correct 43% of confirmed pathogenic mitochondrial point mutations https://www.cell.com/cell/fulltext/S0092-8674(22)00389-0

However, I don't see either base editor entering the clinic for a number of years.

👍️0

jondoeuk 1 년 전

Or it could end up like TRIL. ARCUS has some benefits over current CRISPR systems, manly its size, can edit the mitochondrial genome and IP is not a mess.

👍️0

NY1972 1 년 전

IECure will buy the ARCUS IP when cash is 0 in 18 months.

👍️0

jondoeuk 1 년 전

Not the most productive use of its cash so far. The R&D Day could change that, but the market doesn't seem to think it.

👍️0

NY1972 1 년 전

this is a homeless shelter for PhDs. Cash is not spent on patients. They hired a chief people officer to cut the pie.

👍️0

jondoeuk 1 년 전

The market did not find the recent announcement attractive https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer

I think a reverse split is a possibility, especially after the announcement couldn't move the PPS. If that happens, will likely add fuel to any downward price pressure. Management don't seem the best. Now it's do or die with the in vivo programs.

👍️0

rtrstock 1 년 전

That's what I'm afraid of, guess I'll just wait. Keep my shares.

👍️0

J-mak 1 년 전

In my opinon slim very very slim

👍️0

rtrstock 1 년 전

What's the educated guess?

What's realistically possible by October date for pps to be more than $1.00

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Precision BioSciences Inc (DTIL)

개인 투자자를 위한 전문가급 도구.

DTIL 뉴스

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

DTIL Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Precision BioSciences Inc (DTIL) 뉴스

Precision BioSciences Inc (DTIL)

개인 투자자를 위한 전문가급 도구.

DTIL 뉴스

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

DTIL Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기